Rectal spacers are associated with lower one-year gastrointestinal toxicity after prostate SABR

In 378 prostate SABR patients, rectal spacer use was associated with lower one-year grade ≥1 gastrointestinal toxicity after adjustment (OR 0.31).

KEY POINTS

  • This retrospective analysis of a multicenter BC Cancer registry included 378 men treated with five-fraction prostate SABR at four centers between December 2021 and December 2023. Clinician-reported gastrointestinal (GI) and genitourinary (GU) toxicity was assessed using RTOG/SOMA criteria at 6–8 weeks (n=378) and one year (n=317); the remaining patients had not yet reached the one-year assessment. Median age was 72 years, 74.6% had intermediate-risk disease, and 47.9% received a hydrogel rectal spacer.
  • Treatment used three five-fraction SABR protocols. Most patients (77.8%) received a boosted-CTV regimen prescribing 40 Gy to the prostate CTV and 36.25 Gy to the PTV; 15.6% received a uniform target-volume approach, and 6.6% received prostate plus pelvic nodal irradiation, including 25 Gy to nodal CTVs. Treatment was delivered weekly in 90.5% of patients, and 38.6% received ADT. A small subgroup (1.6%) had low-volume metastatic disease.
  • Grade ≥2 toxicity rates were low at both assessment points, with no reported grade ≥3 GI or GU events. At 6–8 weeks, grade 2 GI and GU toxicity occurred in 1.1% and 5.3%, respectively. At one year, the corresponding rates were 2.2% and 8.8%. Grade 1 GI toxicity decreased from 13.0% to 6.3%, whereas grade 1 GU toxicity remained relatively frequent (31% at 6–8 weeks and 24% at one year).
  • Rectal spacer use was associated with significantly lower one-year grade ≥1 GI toxicity after multivariable adjustment. The unadjusted association was not statistically significant (OR 0.45, 95% CI 0.19–1.06; p=0.07), but adjustment for treatment protocol and baseline GI toxicity yielded adjusted OR 0.31 (95% CI 0.12–0.81; p=0.017). Firth penalized sensitivity analysis produced a similar result (adjusted OR 0.33; p=0.013). The association primarily involved mild symptoms rather than established reductions in grade ≥2 toxicity.
  • Rectal spacers significantly reduced planned intermediate- and high-dose exposure. Within the boosted-CTV subgroup, rectal V18Gy, V29Gy, V33Gy, and V36Gy were all lower among patients receiving spacers (p<0.001). Exploratory analysis linked one-year GI toxicity to rectal dose-volume metrics across approximately V15Gy–V30Gy. For example, rectal V20Gy ≥14 cm³ was associated with increased odds of grade ≥1 GI symptoms (OR 4.9, 95% CI 2.02–11.95; p=0.0003), although these data-derived thresholds require independent validation.
  • Baseline urinary symptoms were important predictors of subsequent GU toxicity. Patients with IPSS ≥8 had greater odds of grade ≥1 GU toxicity at 6–8 weeks (OR 2.01, 95% CI 1.28–3.18; p=0.013) and one year (OR 2.26, 95% CI 1.36–3.81; p=0.009). Prostate volume ≥40 cm³ was also associated with acute grade ≥1 GI toxicity (OR 3.30; p=0.01). Acute GU toxicity correlated with bladder V5Gy–V20Gy, while one-year associations were most evident for V5Gy and mean bladder dose.
  • Spacer use was also associated with increased GU toxicity in unadjusted analyses, with OR 1.61 at 6–8 weeks and OR 1.72 at one year (both p=0.03), although the associations were not significant within the boosted-CTV subgroup. Spacers were preferentially used with higher-dose treatment protocols, and only limited covariates were included in adjusted modeling. Other limitations include retrospective design, planned rather than accumulated dose evaluation, sparse grade 2 events, absent urethral dosimetry, and insufficient follow-up to characterize delayed toxicity.

CLINICAL TAKEAWAY

Hydrogel rectal spacers were associated with reduced planned rectal dose and lower adjusted odds of mild gastrointestinal toxicity at one year following prostate SABR, while baseline urinary symptoms remained a strong predictor of GU morbidity. These observational findings support consideration of rectal separation in selected patients but do not establish a causal reduction in clinically significant late toxicity or justify universal spacer placement.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction